Avalyn Pharma Inc

NEW
NAS:AVLN (USA)  
$ 28.5 -0.29 (-1.01%) 04:00 PM EST
At Loss
Market Cap:
$ 1.26B
Enterprise V:
$ 1.16B
Volume:
110.85K
Avg Vol (2M):
378.54K
Trade In:
Volume:
110.85K
At Loss
Avg Vol (2M):
378.54K

Business Description

Avalyn Pharma Inc
NAICS : 541714 SIC : 2834
ISIN : US05348Y1055
Description
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Name Current Vs Industry Vs History
Cash-To-Debt
82.9
Equity-to-Asset
-1.6
Debt-to-Equity
-0.01
Debt-to-EBITDA
-0.02
Interest Coverage
N/A
N/A
N/A
Piotroski F-Score
N/A/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
55.07
9-Day RSI
51.95
14-Day RSI
50.62
3-1 Month Momentum %
11.63

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
10.19
Quick Ratio
10.19
Cash Ratio
9.82

Dividend & Buy Back

Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
ROA %
-62.33
ROIC %
-795.92
ROC (Joel Greenblatt) %
-7557.28
ROCE %
-72.87
Moat Score
3

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT
-12.67
EV-to-EBITDA
-12.68
EV-to-FCF
-14.14
Earnings Yield (Greenblatt) %
-7.89
FCF Yield %
-6.48

Financials

AVLN's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:AVLN

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Avalyn Pharma Inc Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -2.038
Beta -
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % -
14-Day RSI 50.62
14-Day ATR ($) 2.092126
20-Day SMA ($) 28.258
12-1 Month Momentum % -
52-Week Range ($) 24.15 - 33.32
Shares Outstanding (Mil) 44.33

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Avalyn Pharma Inc Filings

Filing Date Document Date Form
No Filing Data

Avalyn Pharma Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Avalyn Pharma Inc Frequently Asked Questions

What is Avalyn Pharma Inc(AVLN)'s stock price today?
The current price of AVLN is $28.50. The 52 week high of AVLN is $33.32 and 52 week low is $24.15.
When is next earnings date of Avalyn Pharma Inc(AVLN)?
The next earnings date of Avalyn Pharma Inc(AVLN) is .
Does Avalyn Pharma Inc(AVLN) pay dividends? If so, how much?
Avalyn Pharma Inc(AVLN) does not pay dividend.

Guru Commentaries on NAS:AVLN

No articles.

Press Release

Subject Date
No Press Release

Articles on Avalyn Pharma Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1